Acquiring Company
MBK Partners
Acquired Company
Skinidea
Description
MBK Partners is set to acquire Skinidea and Life&bio for approximately 300 billion won. This acquisition gives MBK management control previously held by Morgan Stanley Private Equity. The deal marks MBK's return to management control investments in Korea after two years. The existing management of both companies will remain in place post-transaction.
Don't miss MBK Partners's next move
Get an email the moment MBK Partners makes an acquisition, hires an exec, or expands, usually minutes after it happens.
One email per event. Unsubscribe anytime.
Related People
M&A Insights
Based on deal dataFrequently asked
Who acquired Skinidea?
Skinidea was acquired by MBK Partners, based in Jongno-gu. The deal was reported on September 3, 2026. MBK Partners is one of the largest independent private equity firms in North Asia and has a strong track record of leveraged buyouts and acquisitions across various industries. MBK Partners is privately held and operates in Financial Services.
When did MBK Partners acquire Skinidea?
MBK Partners's acquisition of Skinidea was reported on September 3, 2026. MBK Partners is set to acquire Skinidea and Life&bio for approximately 300 billion won. This acquisition gives MBK management control previously held by Morgan Stanley Private Equity. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Skinidea do?
Skinidea is a beauty brand operator known for its innovative skincare products. The company operates brands such as 'Medipeel' and 'Derma Maison.' It was previously majority-owned by Morgan Stanley Private Equity. It is privately held, operating in Health Care, and is based in South Korea.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick. $29 a month, billed annually, and if it does not pay for itself in a year we refund it.